| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 15
| Issue : 1 | Page : 20-24 |
|
|
Endophthalmitis Postintravitreal Bevacizumab Injections: Incidence, Management, and Visual Outcome in Tertiary Care Center in Pakistan
Amna Rizwan1, Asfandyar Asghar2, Ume Sughra3, Naila Yasmin2
1 Department of Ophthalmology, KEMU, Lahore, Pakistan
2 Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi, Pakistan
3 Department of Community Medicine, Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
Correspondence Address:
Dr. Amna Rizwan
Department of Ophthalmology, KEMU, Lahore
Pakistan
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ojo.ojo_103_21
|
|
|
PURPOSE: The purpose is to study the incidence, characteristics, management, and visual outcome of endophthalmitis postintravitreal bevacizumab (Avastin®) injections.
METHODS: Retrospective cohort study conducted at Fauji Foundation Hospital that is a tertiary care center in Rawalpindi, Pakistan. The study duration was from January 1, 2015 to March 31, 2020. A total of 2321 eyes of 1407 patients were treated with Intravitreal bevacizumab (IVB) in a minor operation theater using standard aseptic measures. We studied the incidence, clinical characteristics, treatment, and visual outcomes of endophthalmitis post-IVB.
RESULTS: Seven eyes (0.30%) out of 2321 eyes developed post-IVB endophthalmitis during the study period. Three eyes (42.8%) were culture positive and four eyes (57.2%) were culture negative. Five eyes (71.4%) showed visual improvement and two eyes (28.6%) did not show visual improvement.
CONCLUSION: Prompt intravitreal antibiotic along with vitreous tap in cases of postintravitreal endophthalmitis may prevent vision loss which provides a useful alternative to immediate pars plana vitrectomy that requires more expertise, equipment, and an operation theater.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
